Moleculin Biotech.jpg
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018
February 21, 2019 16:59 ET | Moleculin Biotech, Inc.
HOUSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug...
Moleculin Biotech.jpg
Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development
February 20, 2019 07:30 ET | Moleculin Biotech, Inc.
HOUSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Biotech.jpg
Moleculin Announces Approval for Third Drug to Commence Clinical Trials
February 07, 2019 07:30 ET | Moleculin Biotech, Inc.
MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in Poland for the treatment of Cutaneous T-Cell...
Moleculin Biotech.jpg
Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug
February 05, 2019 07:30 ET | Moleculin Biotech, Inc.
HOUSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Biotech.jpg
Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board
January 17, 2019 07:30 ET | Moleculin Biotech, Inc.
HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Biotech.jpg
Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland
January 09, 2019 07:30 ET | Moleculin Biotech, Inc.
Received European approval to ship Annamycin into Poland to start treating patients HOUSTON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the...
Moleculin Biotech.jpg
Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate
January 03, 2019 07:30 ET | Moleculin Biotech, Inc.
HOUSTON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Biotech.jpg
REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018
December 11, 2018 07:30 ET | Moleculin Biotech, Inc.
HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Biotech.jpg
Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018
December 06, 2018 16:05 ET | Moleculin Biotech, Inc.
HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Biotech.jpg
Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug
December 06, 2018 07:30 ET | Moleculin Biotech, Inc.
HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...